12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Marqibo vincristine regulatory update

FDA's Oncologic Drugs Advisory Committee voted 7-4, with 2 abstentions, that Talon's Marqibo vincristine has a favorable benefit-risk profile to treat Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in patients with 2 or more relapses or in patients whose cancer has progressed following 2...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >